Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

Kotseva, Kornelia, Wood, David, Backer, Guy De, Bacquer, Dirk De, Pyörälä, Kalevi, Keil, Ulrich, EUROASPIRE Study Group · 2009 · European Journal of Cardiovascular Prevention & Rehabilitation

Abstract

AIM: The aim of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events III (EUROASPIRE III) survey was to determine whether the Joint European Societies' guidelines on cardiovascular prevention are being followed in everyday clinical practice and to describe the lifestyle, risk factor and therapeutic management in patients with coronary heart disease (CHD) in Europe. METHODS: The EUROASPIRE III survey was carried out in 2006-2007 in 76 centres from selected geographical areas in 22 countries in Europe. Consecutive patients, with a clinical diagnosis of CHD, were identified retrospectively and then followed up, interviewed and examined at least 6 months after their coronary event. RESULTS: Thirteen thousand nine hundred and thirty-five medical records (27% women) were reviewed and 8966 patients were interviewed. At interview, 17% of patients smoked cigarettes, 35% were obese and 53% centrally obese, 56% had a blood pressure >or=140/90 mmHg (>or=130/80 in people with diabetes mellitus), 51% had a serum total cholesterol >or=4.5 mmol/l and 25% reported a history of diabetes of whom 10% had a fasting plasma glucose less than 6.1 mmol/l and 35% a glycated haemoglobin A1c less than 6.5%. The use of cardioprotective medication was: antiplatelets 91%; beta-blockers 80%; angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 71%; calcium channel blockers 25% and statins 78%. CONCLUSION: The EUROASPIRE III survey shows that large proportions of coronary patients do not achieve the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. Wide variations in risk factor prevalences and the use of cardioprotective drug therapies exist between countries. There is still considerable potential throughout Europe to raise standards of preventive care in order to reduce the risk of recurrent disease and death in patients with CHD.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjr.0b013e3283294b1d

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 62 references

Research works printed but not linked: 4

  1. Freemantle N, 1999, B/WJ, 318, 1730
  2. Mendis S, 2005, Bulletin World Health Organization, 83, 820
  3. Heidrich J, 2005, Eur J Cardiovasc Prev Rehab, 12, 521
  4. Hobbs R, 2002, Earn Practice, 19, 596

Cited by

See all 812

Metadata

Authors
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group
Affiliations
  • Imperial College London (GB)
  • Ghent University (BE)
  • Department of Medicine, Kuopio University Hospital, Kuopio, Finland
  • University of Münster (DE)
Corresponding author
Wood, David
Venue
European Journal of Cardiovascular Prevention & Rehabilitation
Published
2009-04
Volume
16
Issue
2
Pages
121-137
ISSN
1741-8267 (ISSN-L)
OpenAlex
W2104269881
Cited by
812
References
62
Citations by year
2026: 6 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 20 · 2021: 31 · 2020: 31 · 2019: 39 · 2018: 34 · 2017: 57 · 2016: 52 · 2015: 71 · 2014: 83 · 2013: 80 · 2012: 96
FWCI
59.33
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • European Journal of Cardiovascular Prevention & Rehabilitation (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
coronary artery disease, cardiovascular risk factors, lifestyle, secondary prevention, guideline adherence, smoking, obesity, blood pressure, hypercholesterolemia, diabetes mellitus, antiplatelet therapy, beta-blockers, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, statins
MeSH terms
Aged, Cardiovascular Agents, Coronary Disease, Europe, Female, Humans, Life Style, Male, Middle Aged, Practice Patterns, Physicians', Quality of Health Care, Retrospective Studies, Risk Factors, Treatment Outcome, Practice Guidelines as Topic, Health Care Surveys, Guideline Adherence, Risk Reduction Behavior, Healthcare Disparities, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. https://app.cochat.ai/papers/10.1097/hjr.0b013e3283294b1d
The paper
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group. (2009). EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of Cardiovascular Prevention & Rehabilitation. https://doi.org/10.1097/hjr.0b013e3283294b1d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.